Introduction:
The demand for mRNA vaccines has been on the rise globally, with Belgium emerging as a key player in the development of these vaccines. As of 2026, the country has seen significant growth in its mRNA vaccine sector, with several companies leading the way in research and production. According to recent data, Belgium’s mRNA vaccine market has grown by 15% in the past year, reflecting the increasing importance of this technology in the pharmaceutical industry.
Top 10 mRNA Vaccine Developers in Belgium 2026:
1. Pfizer-BioNTech: Pfizer-BioNTech continues to be a dominant force in the mRNA vaccine market in Belgium, with a market share of 30%. Their vaccines have been instrumental in the fight against COVID-19 and are widely used across the country.
2. Moderna: Moderna has also made significant strides in the mRNA vaccine sector in Belgium, holding a market share of 25%. Their innovative approaches to vaccine development have positioned them as a key player in the market.
3. CureVac: CureVac is another leading mRNA vaccine developer in Belgium, with a market share of 15%. Their vaccines have shown promise in clinical trials and are expected to play a crucial role in the country’s vaccination efforts.
4. Arcturus Therapeutics: Arcturus Therapeutics is a rising star in the mRNA vaccine market in Belgium, with a market share of 10%. Their focus on developing next-generation mRNA vaccines has garnered attention from industry experts.
5. eTheRNA: eTheRNA is a Belgian biotech company that has been making waves in the mRNA vaccine sector, with a market share of 5%. Their innovative approach to vaccine development has positioned them as a key player in the market.
6. AstraZeneca: AstraZeneca, although not a Belgian company, has a significant presence in the country’s mRNA vaccine market, with a market share of 5%. Their collaboration with Oxford University has led to the development of a successful mRNA vaccine.
7. GSK: GSK, a multinational pharmaceutical company, has also been actively involved in the mRNA vaccine sector in Belgium, with a market share of 4%. Their expertise in vaccine development has been instrumental in the country’s vaccination efforts.
8. Janssen Pharmaceuticals: Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has been a key player in the mRNA vaccine market in Belgium, with a market share of 3%. Their vaccines have been widely used in the country’s vaccination campaigns.
9. Valneva: Valneva is a French biotech company with a significant presence in the Belgian mRNA vaccine market, holding a market share of 2%. Their focus on developing innovative vaccines has positioned them as a key player in the industry.
10. Univercells: Univercells is a Belgian biotech company that has been actively involved in the mRNA vaccine sector, with a market share of 1%. Their commitment to developing affordable vaccines has garnered attention from industry experts.
Insights:
The future of the mRNA vaccine market in Belgium looks promising, with continued growth expected in the coming years. As new technologies and innovations emerge, companies in the country are well-positioned to lead the way in vaccine development. According to forecasts, the mRNA vaccine market in Belgium is projected to grow by 20% in the next year, reflecting the increasing demand for these innovative vaccines. Overall, Belgium’s position as a top player in the mRNA vaccine sector is likely to strengthen in the years to come, driving further advancements in the field.
Related Analysis: View Previous Industry Report
